The DOI matches its Crossref record.
Research Reporting Standards for Radioembolization of Hepatic Malignancies
Open accessAbstract
Primary Liver Tumors Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver; its incidence is increasing worldwide. It ranks as the sixth most common tumor and third most common cause of cancer-related mortality (1,2). Primary liver tumors include HCC and intrahepatic cholangiocarcinoma. Surgical resection is preferred over transplantation and is considered potentially curative in patients with resectable HCC and normal liver function (3). Transplantation is considered the gold standard for patients with unresectable HCC and whose disease is within the Milan criteria (4). Resection and transplantation have limited roles, given advanced disease (chronic liver disease and/or tumor extent) at presentation and limited organ availability (5–7). Chemoembolization and radiofrequency ablation represent standard therapies in treating patients and serve as a bridge to transplantation in selected patients (8,9). Radioembolization has an emerging role in “bridging” patients within criteria by delaying tumor progression. It has also been shown to downstage disease beyond the Milan, to within, transplant criteria (10–12). A recent study has demonstrated that radioembolization leads to longer time-to-progression and better toxicity profile when compared with chemoembolization (13). Patients with macrovascular tumor involvement have also exhibited evidence of clinical benefit after radioembolization (14).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationEpidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Self-citationYttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
Salem, R., Johnson, G. E., Kim, E., Riaz, A., Bishay, V., Boucher, E., Fowers, K., Lewandowski, R., & Padia, S. A. (2021) · Hepatology · doi:10.1002/hep.31819 · Cited by 555
Self-citationPositron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., Ayav, A., Campillo-Gimenez, B., Beuzit, L., Pracht, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3702 · Cited by 306
Self-citation
Metadata
- Authors
- Salem, R., Lewandowski, R. J., Gates, V. L., Nutting, C. W., Murthy, R., Rose, S. C., Soulen, M. C., Geschwind, J.-F. H., Kulik, L., Kim, Y. H., Spreafico, C., Maccauro, M., Bester, L., Brown, D. B., Ryu, R. K. W., Sze, D. Y., Rilling, W. S., Sato, K. T., Sangro, B., Bilbao, J. I., Jakobs, T. F., Ezziddin, S., Kulkarni, S., Kulkarni, A., Liu, D. M., Valenti, D., Hilgard, P., Antoch, G., Muller, S. P., Alsuhaibani, H., Mulcahy, M. F., Burrel, M., Real, M. I., Spies, S., Esmail, A. A., Raoul, J.-L., Garin, E., Johnson, M. S., Benson, A. B., Sharma, R. A., Wasan, H., Lambert, B., Memon, K., Kennedy, A. S., & Riaz, A.
- Venue
- Journal of Vascular and Interventional Radiology
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 22
- Issue
- 3
- Pages
- 265-278
- ISSN
- 1051-0443 (ISSN-L)
- OpenAlex
- W2034342132
- Cited by
- 200
- References
- 0
- FWCI
- 12.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Research Reporting Standards for Radioembolization of Hepatic Malignancies. https://app.cochat.ai/papers/10.1016/j.jvir.2010.10.029
- The paper
- Salem, R., Lewandowski, R. J., Gates, V. L., Nutting, C. W., Murthy, R., Rose, S. C., Soulen, M. C., Geschwind, J.-F. H., Kulik, L., Kim, Y. H., Spreafico, C., Maccauro, M., Bester, L., Brown, D. B., Ryu, R. K. W., Sze, D. Y., Rilling, W. S., Sato, K. T., Sangro, B., . . . Riaz, A. (2011). Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology. https://doi.org/10.1016/j.jvir.2010.10.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.